Iovance Biotherapeutics (IOVA) Other Operating Expenses (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Other Operating Expenses for 8 consecutive years, with $51.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Operating Expenses rose 0.51% year-over-year to $51.0 million; the TTM figure through Mar 2026 stood at $207.9 million (down 13.7% YoY), while the FY2025 annual figure was $209.2 million, up 59.85% from the prior year.
• Other Operating Expenses declined to $51.0 million in Q1 2026 per IOVA's latest filing, from $52.7 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $117.4 million in Q4 2024 and bottomed at $2.0 million in Q2 2023.
• Historically, Other Operating Expenses has averaged $39.9 million across 4 years, with a median of $44.4 million in 2024.
• Annual changes were most pronounced in 2024 — Other Operating Expenses soared 1430.15% — and 2025, when it sank 55.15%.
• Iovance Biotherapeutics' Other Operating Expenses stood at $16.1 million in 2023, then jumped by 631.04% to $117.4 million in 2024, then tumbled by 55.15% to $52.7 million in 2025, then decreased by 3.1% to $51.0 million in 2026.
• Business Quant data shows IOVA's Other Operating Expenses at $51.0 million in Q1 2026, $52.7 million in Q4 2025, and $47.5 million in Q3 2025.